Lisa Higgins
Family · Hanford, CANPI 1477956688
Payments from drug & device makers
Across 899 payments — averaging $345.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$161K
- Novo Nordisk$95K
- Corcept Therapeutics$46K
- Amgen$3K
- Insulet Corporation$2K
- AstraZeneca$1K
- plus $3K from 20 others
What the payments were for
- Consulting fees$1,5631%
- Speaking & faculty fees$258,65983%
- Travel & lodging$32,76711%
- Food & beverage$17,0625%
- Education$7930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 268 | $160,623 |
| Novo Nordisk | 247 | $95,024 |
| Corcept Therapeutics | 91 | $46,199 |
| Amgen | 110 | $2,618 |
| Insulet Corporation | 15 | $2,261 |
| AstraZeneca(2 entities) | 39 | $1,258 |
| Lilly USA, LLC | 28 | $569 |
| Bayer | 17 | $535 |
| Xeris Pharmaceuticals, Inc. | 9 | $366 |
| Novartis | 13 | $211 |
| Dexcom, Inc. | 7 | $209 |
| Esperion Therapeutics, Inc. | 18 | $166 |
| Abbott | 10 | $158 |
| AbbVie | 7 | $136 |
| Edwards Lifesciences | 1 | $116 |
| Sanofi-aventis U.S. LLC | 3 | $86 |
| Mannkind Corporation | 3 | $56 |
| BD | 2 | $45 |
| Tandem Diabetes Care, Inc. | 3 | $42 |
| Amarin Pharma, Inc. | 2 | $37 |
| Kyowa Kirin, Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Vistapharm, Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Nevro Corp. | 1 | $16 |
| Qiagen, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$90,345
- RYBELSUS$54,258
- Korlym$45,151
- MINIMED 770G$31,900
- Ozempic$30,834
- Minimed 770G System$27,608
- Omnipod$2,000
- Minimed 630G$1,000
- TEZSPIRE$558
- Kerendia$330
- Repatha$243
- FARXIGA$232
- RECORLEV$180
- EVENITY$118
- MOUNJARO$118
- Edwards SAPIEN 3 Transcatheter Heart Valve$116
- GUARDIAN SENSOR (3)$112
How this compares
$310,844 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 30 | $486,096 |
| OzempicSemaglutide | 295 | $400,446 |
| JardianceEmpagliflozin | 197 | $200,881 |
| Repatha SureclickEvolocumab | 111 | $122,499 |
| MounjaroTirzepatide | 105 | $110,787 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $101,830 |
| RybelsusSemaglutide | 58 | $98,608 |
| FarxigaDapagliflozin Propanediol | 87 | $79,784 |
| Tresiba Flextouch U-100Insulin Degludec | 113 | $68,037 |
| TradjentaLinagliptin | 22 | $24,422 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $18,925 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 19 | $18,690 |
| NovologInsulin Aspart | 32 | $17,242 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $16,382 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $13,266 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $95,024 | $516,296385 claims |
| Corcept TherapeuticsKorlym | $46,199 | $486,09630 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr | $25 | $253,805255 claims |
| Lilly USA, LLCMounjaro, Humalog | $569 | $123,217140 claims |
| AstraZenecaFarxiga | $1,258 | $79,78487 claims |
| MerckJanumet Xr, Januvia | $23 | $23,44532 claims |
| AbbVieSynthroid | $136 | $2,09828 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Hanford
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
- Phyllis CasonLos Angeles$187K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.